Market Overview

UPDATE: JP Morgan Reiterates Incyte Corporation at Overweight Following PML Case

Share:
Related INCY
Benzinga's Top Initiations
Pipeline Momentum Makes Biotech Stock Incyte Worth Watching
The Vetr community has downgraded $INCY to 3-Stars (Vetr)

JP Morgan reiterated Incyte Corporation (NASDAQ: INCY) with an Overweight rating.

JP Morgan analyst Cory Kasimov noted, "Shares of INCY have been under pressure this morning following disclosure that a case of PML was identified in a 75 yr old male myelofibrosis (MF) patient from the UK treated with Jakafi. While it has not yet been determined whether this development was related to the use of Jakafi, we are unsurprised by the market's reaction given the theoretical risk (however unlikely) this could represent for Jakafi in MF and eventually PV. Nevertheless, we're hesitant to jump to conclusions in this instance with just one case identified to date (in almost 10,000 pts treated) and the rapid onset of PML following initiation of Jakafi treatment."

Incyte Corporation closed at $24.84 on Friday.

Latest Ratings for INCY

DateFirmActionFromTo
Aug 2015BarclaysInitiates Coverage onOverweight
Aug 2015JMP SecuritiesMaintainsMarket Outperform
May 2015Bank of AmericaInitiates Coverage onBuy

View More Analyst Ratings for INCY
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Reiteration Analyst Ratings

 

Related Articles (INCY)

Get Benzinga's Newsletters